Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Praluzatamab Ravtansine in Advanced Breast Cancer
NCT04596150Phase 2Completed
- Sponsor
- CytomX
- Start
- Dec 2020
- Primary completion
- Jun 2023
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
A Phase 2 trial of praluzatamab ravtansine in breast cancer, sponsored by CytomX. Started Dec 2020; status: completed.
02
Drugs
praluzatamab ravtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04596150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04596150.